In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actelion: A Model for European Biotech

Executive Summary

Actelion reached profitability in record time by focusing from the start on the development and commercial end of the business. It in-licensed an unusually late-stage pipeline made up of compounds its founders helped develop, and built its own global sales and marketing infrastructure to maximize the value of its projects. Now Actelion plans to leverage growing profits to go back and nurture earlier stage research-a top-down biotech-building model that may prove inspirational to others.

You may also be interested in...

Actelion Punches Back Against Activist Shareholder

Actelion's board vice-chairman Joe Scodari highlights 'fallacies' in activist shareholder's call for sale.

Actelion Follows Innovation into GP Markets

Actelion has become Europe's most successful R&D-based biotech largely on the success of Tracleer for PAH, a specialist indication. Now, facing competition in PAH, but in line with its strategy of following innovation wherever it leads, the company's starting to build a primary care-focused commercial operation to support GP-targeted pipeline assets. That takes Actelion into a very new game, and risks destroying the laissez-faire culture seen as crucial to its unusually high R&D productivity. But Actelion reckons a well-planned, step-wise, and nimble approach to primary care marketing will allow it to retain both the maximum value from its drugs, and its biotech-ness.

Spin-Out Step-Ups Reflect Bulk, Not Risk

An analysis of a group of Big Pharma and big biotech spin-outs, which tend to raise more private money than their build-from-scratch bretheren, shows that while these firms are certainly heftier--and often considered better equiped to succeed in the public markets--their pre-money step-ups are in the end, nothing special.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts